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ABSTRACT
The suppressor of Lin-12-like (C. elegans) (SEL1L) is involved in the endoplasmic 
reticulum (ER)-associated degradation pathway, malignant transformation and 
stem cells.
In 412 formalin-fixed and paraffin-embedded brain tumors and 39 Glioblastoma 
multiforme (GBM) cell lines, we determined the frequency of five SEL1L single 
nucleotide genetic variants with regulatory and coding functions by a SNaPShotTM 
assay. We tested their possible association with brain tumor risk, prognosis and 
therapy.
We studied the in vitro cytotoxicity of valproic acid (VPA), temozolomide (TMZ), 
doxorubicin (DOX) and paclitaxel (PTX), alone or in combination, on 11 GBM cell lines, 
with respect to the SNP rs12435998 genotype.
The SNP rs12435998 was prevalent in anaplastic and malignant gliomas, and 
in meningiomas of all histologic grades, but unrelated to brain tumor risks. In GBM 
patients, the SNP rs12435998 was associated with prolonged overall survival (OS) 
and better response to TMZ-based radio-chemotherapy. GBM stem cells with this SNP 
showed lower levels of SEL1L expression and enhanced sensitivity to VPA.
INTRODUCTION
Primary brain tumors consist of tumors with 
neuroepithelial and/or mesodermal origin. The former 
are prevailingly gliomas and represent the greatest part, 
whereas meningiomas are the most frequent mesodermal 
tumors. Gliomas can be subdivided in astrocytic and 
oligodendroglial and, for clinical purpose, in low grade 
and high grade tumors, among which Glioblastoma 
multiforme (GBM) is the most frequent tumor type. 
Gliomas are classified in four histologic grades in 
agreement with the World Health Organization (WHO) 
criteria [1]. The two main features of GBM are the 
phenotypic and genotypic heterogeneity, and the cell 
resistance to therapy.
GBM has a median overall survival (OS) of six 
months after surgery, 12.1 months after radiotherapy (RT) 
and 14.6 months after adjuvant chemotherapy (CHT) by 
temozolomide (TMZ) [2].
Gliomagenesis is a rather complicated process. It 
requires the existence of a proliferative neuroepithelial 
tissue, characterized by genotypic and phenotypic 
heterogeneity [1]. Mutation accumulation and epigenetic 
events are responsible for their final molecular asset.
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The etiology of gliomas is largely unknown. 
Familial aggregation and identification of common and 
rare susceptibility genetic variants suggest the presence 
of genetic predisposition. The number of presently known 
variants accounts for only a small proportion of cases 
[3, 4] and, therefore, additional genetic variants need 
to be discovered by genome-wide association studies. 
However, the high genetic heterogeneity does not favor 
the identification of new options for a targeted therapy and 
a better prediction of patient survival time [5, 6].
The current glioma treatment is based on 
a combination of surgical resection and TMZ-based 
RT-CHT, although the highly invasive growth of these 
tumors is responsible for the lack of a local control [2, 7]. 
Conformational RT is only temporarily effective, since 
infiltrating and migrating cells escape its effect, whereas 
whole brain irradiation damages the normal nervous 
tissue [8]. The benefits of RT may not outweigh the side 
effects caused by radiation damage [9]. TMZ has proven 
to slightly improve the median OS by three months in 
GBM patients and it is more effective in patients with 
MGMT promoter hypermethylation [7]. The adjuvant 
treatment with procarbazine, lomustine (CCNU) and 
vincristine (PCV) combination gave some improvement 
on the progression free survival (PFS), but not on 
OS, in anaplastic astrocytomas and in pure and mixed 
oligodendrogliomas [10].
Meningiomas are benign tumors, mostly of 
WHO grade I; WHO grade II (atypical) and, especially, 
WHO grade III (anaplastic) tumors are much rarer and 
characterized by a less favorable prognosis.
The suppressor of Lin-12-like (C. elegans) (SEL1L) 
gene (OMIM 602329) is a putative tumor suppressor 
gene involved in the endoplasmic reticulum (ER)-
associated degradation (ERAD) pathway implicated 
in tumor progression [11, 12]. Recently, SEL1L was 
found to be down-regulated in pancreatic ductal 
adenocarcinoma (PDA) [13, 14] by aberrant up-regulation 
of few microRNAs (hsa-mir-143, hsa-mir-155 and hsa-
mir-223) that became potential therapeutic targets [15]. 
Interestingly, the single nucleotide polymorphism (SNP) 
rs12435998 in SEL1L intron 3 has been reported to 
modify the age at diagnosis of Caucasian nonsmoker PDA 
patients, for which it was proposed as a diagnostic and 
prognostic marker [14].
SEL1L is involved in several other neoplasia 
[16–20]. Its reduced protein expression by RNA 
interference increases GBM stem cell sensitivity to 
valproic acid (VPA) treatments [21]. SEL1L also plays a 
role in the neural stem cell self-renewal [22].
In the current study, we analyzed five genetic 
variants within SEL1L with potential regulatory and 
coding functions and their possible association with 
brain tumor risk, prognosis and response to therapies. 
Furthermore, we tested the influence of the SNP 
rs12435998 on the in vitro cytotoxicity of GBM cell lines 
treated with different pharmacological agents.
RESULTS
SEL1L genotyping in brain tumors
Five genetic variants were genotyped in 328 gliomas 
and 84 non-glial tumors from Caucasian patients with 
diagnosis of brain tumors. All frequencies were in Hardy-
Weinberg equilibrium. Of the genetic variants analyzed, 
only the SNPs rs12435998 (c.–88T > C) and rs11499034 
(p.Asp162Gly) were detected in both glial and non-glial 
tumor series.
In gliomas, the SNP rs12435998 was found with 
a minor allele frequency (MAF) of 100/644 (0.155) 
(Table 1). It was present in astrocytic, pure and mixed 
oligodendroglial tumors of all histologic grades, with 
higher frequency in anaplastic (20/104, 0.192) than in 
low grade tumors (16/138, 0.116) (pF = ns), and in GBMs 
(63/186, 0.168) (Tables 1–3). In the latter, no difference 
in the allelic frequencies was found between primary 
(61/360, 0.169) and secondary tumors (2/12, 0.167) 
(Table 3).
When compared to Italian healthy controls 
(MAF = 0.144) [23] or to European CEU individuals 
(MAF = 0.181, NCBI), the allelic frequency observed in 
gliomas was not distributed in a significantly different way. 
The SNP rs12435998 was always found in heterozygosity 
with the exception of one pGBM (CTO3), carrier of the 
CC genotype, and originating in culture both NS and AC. 
In non-glial tumors, the SNP rs12435998 was identified 
in all represented tumor types, with higher frequencies in 
ependymomas (7/20, 0.35) and meningiomas (21/102, 
0.206) (Table 4).
The SNP rs11499034 was detected in glial tumors 
with MAF of 14/640 (0.0218) (Table 1). It was found 
in pure oligodendroglial tumors (7/184, 0.038) of both 
histologic grades, as well as in malignant astrocytic 
tumors (7/386, 0.0181) (Tables 1–3). Interestingly, 
one pGBM (CV20) generating NS was found to be 
compound heterozygous for the SNPs rs12435998 and 
rs11499034. When compared with Italian healthy controls 
(MAF = 0.010) [24] or to European CEU individuals 
(MAF = 0.013, NCBI), the SNP rs11499034 allelic 
frequency in oligodendroglial tumors was not differently 
distributed (pF = ns). In non-glial tumors, the SNP 
rs11499034 was identified in Schwannomas (2/30, 0.067) 
and medulloblastomas (1/16, 0.063) (Table 4). It was 
always found in heterozygosity.
The two c.–366T > C and c.–354T > C genetic 
variants in the promoter region were rare variants 
(MAF < 0.01), in complete linkage disequilibrium. 
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Table 1: Gene frequencies of SEL1L nucleotide genetic variants in gliomas
Sequence 
variation
Minor 
allele
PA  
(N = 30)*
DA  
(N = 26)*
AA  
(N = 14)*
GBM  
(N = 372)*
O  
(N = 90)*
AO  
(N = 74)*
OA  
(N = 18)*
AOA  
(N =16)*
c.–366T > C C 0.00 0.00 0.00 0.01 0.00 0.014 0.00 0.00
c.–354T > C C 0.00 0.00 0.00 0.01 0.00 0.014 0.00 0.00
c.341–88T > C C 1(0.033) 4(0.167) 3(0.214) 63(0.169) 11(0.115) 12(0.162) 1(0.056) 5(0.31)
p.Asp162Gly G 0.00 0.00 1(0.071) 6(0.0161) 5(0.056) 2(0.027) 0.00 0.00
p.Ser658Pro C 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Abbreviations: SEL1L, suppressor of Lin-12-like; PA, pilocytic astrocytoma; DA, diffuse astrocytoma; AA, anaplastic 
astrocytoma; GBM, glioblastoma multiforme; O, oligodendroglioma; AO, anaplastic oligodendroglioma; OA, 
oligoastrocytoma; AOA, anaplastic oligoastrocytoma.
*Number of alleles.
Table 2: Gene frequency of SEL1L SNPs rs12435998 and rs11499034 in glioma subtypes
Tumor subtype Patients 
(N )*
SEL1L 
rs12435998
p value Patients 
(N )*
SEL1L 
rs11499034
p value
Astrocytic tumors (WHO Grades I–IV) 444 71 (0.167) Ns 444 7 (0.16) Ns
       
Oligodendroglial tumors (WHO Grades II–III) 186 23 (0.123) Ns 184 7 (0.38) 0.0072**
       
Oligoastrocytic tumors (WHO Grades II–III) 34 6 (0.176) Ns 34 0 (0.00) Ns
Abbreviations: SEL1L, suppressor of Lin-12-like; SNP, single nucleotide polymorphism; WHO, World Health Organization; 
Ns, not significant.
*Number of alleles.
**Case-control study with control frequencies from Saltini et al, 2004 [24].
They were identified in one anaplastic oligodendroglial 
tumor and in one pGBM among gliomas and in one 
medulloblastoma within non-glial tumors (Tables 2, 4).
The p.Ser658Pro missense variation was never 
found in both tumor series.
The constitutional nature of each polymorphic SNP 
was demonstrated by comparison of matched tumor and 
blood/saliva samples from 41 patients.
Relationship of the SNP rs12435998 with clinical 
and molecular features
The SNP rs12435998 was not associated with sex, 
patient age (≤ 50 or > 50 years), tumor location or age at 
diagnosis both in glial and non-glial tumors (p > 0.05 for 
all categories).
In low and high grade gliomas of the present 
series, the frequency of the SNP rs12435998 was 
compared with a series of genetic and epigenetic 
alterations (IDH1/2 somatic mutations, EGFR gene 
amplification, MGMT promoter hypermethylation, TP53 
mutations or TERT promoter mutations [personal data], 
1p/19q chromosome status, already published [25–28]. 
No association was found with any of them (p > 0.05 
for all).
SEL1L genotyping in GBM cell lines
All genetic variants were genotyped in the panel 
of 39 GBM cell lines and in two neuralized pluripotent 
human control cell lines.
The SNPs rs12435998, rs11499034 and the 
c.–366T > C and c.–354T > C genetic variants found 
in tumors were also detected in the derived GBM 
cell lines. Out of the 16 NS, seven (CV1 NS, CV10 
NS, CV20 NS, NO4 NS, CTO3 NS, CTO15 NS and 
010627 NS) carried the SNP rs12435998, one (CV20 
NS) also the SNP rs11499034 whereas another one 
(CTO5 NS) the two c.–366T > C and c.–354T > C 
genetic variants (supplementary Table S1). Six out of 
the former seven (CV1 NS, CV10 NS, CV20 NS, NO4 NS 
and CTO15 NS and 010627 NS) carried the rs12435998 
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Table 3: Gene frequency of SEL1L SNPs rs12435998 and rs11499034 in gliomas according to WHO 
grading
Tumor type Patients (N )* SEL1L rs12435998 MAF SEL1L rs11499034 MAF
WHO Grade I    
Pilocytic astrocytoma 15 1 (0.033) 0 (0.00)
WHO Grade II    
Diffuse and gemistocytic 
astrocytoma 12/13 4 (0.167) 0 (0.00)
Oligodendroglioma 48/49 11 (0.122) 5 (0.057)
Oligoastrocytoma 9/9 1 (0.056) 0 (0.00)
Total 69 16 (0.116) 5 (0.38)
WHO Grade III    
Astrocytoma 7 3 (0.214) 1 (0.71)
Oligodendroglioma 37 12 (0.162) 2 (0.27)
Oligoastrocytoma 8 5 (0.313) 0 (0.00)
Total 52 20 (0.192) 3 (0.029)
WHO Grade IV    
pGBM 180 61 (0.169) 6 (0.18)
sGBM 6 2 (0.167) 0 (0.00)
Total 186 63 (0.168) 6 (0.016)
Abbreviations: SEL1L, suppressor of Lin-12-like; SNP, single nucleotide polymorphism; WHO, World Health 
Organization; MAF, minor allele frequency; GBM, glioblastoma multiforme; pGBM, primary GBM; sGBM, secondary 
GBM.
*Number of alleles.
TC genotype whereas the other (CTO3 NS) the CC 
genotype. The rs11499034, c.–366T > C and c.–354T > 
C variants were in a heterozygous status. Out of the 18 
AC, eight (CV4 AC, CV6 AC, CV9 AC, CV10 AC, NO2 
AC, NO4 AC, CTO15 AC and 010627 AC) carried the 
rs12435998 TC genotype and one (CTO5 AC) both the 
c.–366T > C and c.–354T > C variants in a heterozygous 
status. Within the five cell lines from coated matrix, one 
(G179) displayed the rs12435998 TC genotype whereas 
the two neuralized pluripotent human control stem cell 
lines carried the wild type genotype (supplementary 
Table S1).
Table 4: Gene frequencies of SEL1L nucleotide genetic variants in non-glial tumors
Nucleotide variation Minor allele Schwannoma 
(N = 30)*
Ependymoma 
(N = 20)*
Meningioma 
(N = 102)*
Medulloblastoma 
(N = 16)*
c.–366T > C C 0.00 0.00 0.00 1(0.063)
c.–354T > C C 0.00 0.00 0.00 1(0.063)
c.341–88T > C C 5(0.167) 7(0.350) 21(0.206) 1(0.063)
p.Asp162Gly G 2(0.067) 0.00 0.00 1(0.063)
p.Ser658Pro C 0.00 0.00 0.00 0.00
Abbreviations: SEL1L, suppressor of Lin-12-like.
*Number of alleles.
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Figure 1: Relationship between the SEL1L SNP rs12435998 and survival in GBM patients. A. Kaplan-Meier survival 
curves for overall survival (OS) in GBM patients with respect to the SEL1L SNP rs12435998 genotype. B. Kaplan-Meier survival curves 
for OS in the subgroup of 55 GBM patients treated with TMZ-based RT-CHT with respect to the SEL1L SNP rs12435998 genotype.
Abbreviations: SEL1L, suppressor of lin-12-like; SNP, single nucleotide polymoprphism; GBM, glioblastoma multiforme; OS, overall 
survival; SNP, single nucleotide polymorphism; Cum, cumulative.
In silico analysis of SEL1L genetic variants
By in silico analysis, the p.Asp162Gly (rs11499034) 
missense variation was predicted to be possibly damaging 
by PolyPhen-2, contrarily to SNAP and pMUT tools 
predicting a neutral effect.
For the SNP rs12435998, two distinct bioinformatic 
tools (ESE Finder and Human Splicing Finder) predicted 
a possible functional effect since the minor allele C 
creates a putative exonic splicing enhancer (ESE) motif 
responsive to the serine/arginine-rich (SR) protein SC35. 
The nucleotide variant generates a cis sequence element 
important for both the correct splice site identification and 
the regulation of alternative splicing. This ESE motif acts 
as binding site for the splicing factor SC35, a member of 
the spliceosome required for the formation of the earliest 
ATP-dependent splicing complex.
Survival analysis
The relationship of the SNP rs12435998 with OS 
was evaluated in 137 GBM patients and in 58 patients 
with oligodendroglial neoplasia. In the former, the SNP 
rs12435998 was identified in 44 patients (48/274, 0.175), 
including 40 TC heterozygote and 4 CC homozygote cases 
that were considered as a single group. By univariate 
analysis, the SNP rs12435998 minor allele C improved 
patient OS (p = 0.046, Log Rank test), regardless of the 
post-surgical treatment (Figure 1A). The median survival 
time was 14 months for TC/CC genotype carriers and 
12 months for wild type patients. Censored cases were 
12/44 (0.273) for the former and 12/93 (0.129) for the 
latter. In the group of 55 patients treated according to 
Stupp’s protocol [2], the SNP rs12435998 minor allele 
C was significantly associated to a better response 
to TMZ based RT-CHT (p = 0.011, Log Rank test) 
(Figure 1B). The median survival time was 18 months 
for TC/CC genotype carriers and 13 months for wild 
type patients. Censored cases were 7/20 (0.35) for the 
former and 3/35 (0.086) for the latter. With respect to the 
MGMT promoter hypermethylation status in the same 
group of patients, the SNP rs12435998 minor allele C 
improved OS in both methylated and unmethylated cases, 
more evidently in the former than in the latter (data not 
shown).
The SNP rs12435998 minor allele C did not improve 
patient OS (p = 0.540, Log Rank test) in the subgroup of 
34 patients that received RT as single treatment (data not 
shown).
In oligodendroglioma patients, the SNP rs12435998 
minor allele C was identified in 17 patients (34/116, 
0.293), including 16 TC heterozygote and 1 CC 
homozygote cases that were considered as a single group. 
Univariate analysis revealed that the SNP rs1243599 did 
not affect patient OS (data not shown). Censored cases for 
wild type patients were 8/17 (0.47) and 26/41 (0.63) for 
TC/CC genotype carriers, respectively.
SEL1L, SOX2, NOTCH1 and Gadd45β expression in 
GBM cell lines with respect to the SNP rs12435998 
and culture conditions
SEL1L expression was evaluated in 18 GBM 
cell lines carrying different genotypes of the SNP 
rs12435998, in order to evaluate the influence on the 
mRNA. Five of these (CV1 NS, CV13 NS, CTO5 NS, 
NO6 NS and 010627 NS) were derived and grew as NS, 
six (CV2 AC, CV6 AC, CV9 AC, CV10 AC, CV17 AC 
and U87-MG AC) as AC, three (CV21, CTO3 and NO3) 
both as AC and NS, and one (G166) in coated matrix. 
Lower SEL1L mRNA expression levels were observed 
in NS compared to AC, and the minor allele C appeared 
to be associated in the former to lower SEL1L expression 
levels (Figure 2A). We also evaluated SOX2 and NOTCH1 
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Figure 2: SEL1L expression levels by qRT-PCR and analysis of SEL1L alternative transcripts in GBM cell lines.  
A. SEL1L expression levels in NS and AC cultures with respect to the SEL1L SNP rs12435998 genotype. B. Analysis of SEL1L alternative 
transcripts in the same panel of GBM cell lines with respect to the SEL1L SNP rs12435998 genotype. 
Abbreviations: SEL1L, suppressor of lin-12-like; qRT-PCR, quantitative real time (qRT)-PCR; GBM, glioblastoma multiforme; 
SNP, single nucleotide polymorphism; NS, neurospheres; AC, adherent cells.
gene expression and we found higher levels in NS 
compared to AC (Figure 3), with the exception of 
CTO3 cell line (carrying the CC genotype) where their 
expression was always high in both NS and AC. In 
contrast, the Gadd45β gene expression was higher in AC 
than in NS (Figure 3).
SEL1L did not generate a spliced transcript as 
demonstrated by the absence of additive amplified PCR 
products using a primer set designed against SEL1L cDNA 
flanking the intron 3 (Figure 2B).
SEL1L protein expression with respect to the 
SNP rs12435998
Western blotting analysis performed on 11 GBM 
cell lines with a mouse monoclonal and a goat polyclonal 
anti-SEL1L antibody raised against the N-terminus 
region revealed the presence of additive bands in NS, 
carrying either the rs12435998 wild type or CC genotype 
(Figure 4A, 4B). Indeed, besides the well-known ER 
anchored protein with molecular weight of 95 kDa and 
the smaller secreted variant of 38 kDa, an additional band 
of approximately 260 kDa is clearly visible in NS but not 
in AC, regardless of the nucleotide variant, using both 
the monoclonal and the polyclonal anti-SEL1L antibody 
(Figure 4A, 4B).
Drug treatments and cytotoxicity assay
By MTT analyses and cell counts VPA displayed 
a dose-dependent inhibitory effect on the in vitro 
proliferation of all GBM cell lines, both NS and AC 
(unpublished data). A drug concentration of 2 mM allowed 
to significantly reduce the viability of all tested cell lines. 
Moreover, the cytotoxic action of the drug appeared more 
evident on NS that on the correspondent AC from the 
same tumor (where it was available). We observed that 
NS carrying either the TC or the CC genotype showed a 
higher sensitivity to VPA (32.55% and 37.6% viability 
reduction, respectively) compared to NS with wild type 
genotype (18.14% average viability reduction from four 
different cell lines). In AC, a relationship between VPA 
cell response and genotype was not so evident, even if 
the sample size does not allow meaningful conclusions 
(Figure 5A).
The combined treatment of VPA with TMZ, 
DOX or PTX resulted in a significant increase of the 
anti-proliferative effect compared to single treatments 
on the most cell lines. The range of viability reduction 
for the combined treatment in comparison with the 
drug alone was 1.72%–33.94% (min value-max value) 
for VPA + TMZ, 6.78%–27.91% for VPA + DOX, 
3.06–14.63% for VPA + PTX, regardless of the culture 
conditions (Figure 5B–5D). Compared to the control, the 
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Figure 4: Western blotting analysis for SEL1L in GBM cell lines. SEL1L expression in NS and AC with respect to the SEL1L 
SNP rs12435998 genotype using a monoclonal A. and a polyclonal B. anti-SEL1L antibody. 
Abbreviations: SEL1L, suppressor of lin-12-like; NS, neurospheres; AC, adherent cells; SNP, single nucleotide polymorphism; 
GBM, glioblastoma multiforme; NS, neurospheres; AC, adherent cells.
Figure 3: SOX2, NOTCH1 and Gadd45β expression levels by qRT-PCR in GBM cell lines. SOX2, NOTCH1 and Gadd45β  
expression levels by qRT-PCR in the same panel of GBM cell lines (NS and AC) with respect to the SEL1L SNP rs12435998 genotype. 
Abbreviations: qRT-PCR, quantitative real time (qRT)-PCR; GBM, glioblastoma multiforme; SNP, single nucleotide polymorphism; 
NS, neurospheres; AC, adherent cells.
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average viability reduction for the combined treatment 
with respect to NS and AC culture conditions was 15.60% 
and 13.90%, respectively, for VPA + TMZ, 15.46% 
and 7.93% for VPA + DOX and 10.86% and 8.38% for 
VPA + PTX.
The greatest anti-proliferative effect was 
found for the combined treatment of VPA + TMZ. 
It was significantly more effective than TMZ alone 
in all cell lines, with the exception of one case 
(CTO15 NS and CTO15 AC). The enhancement of 
the response was especially observed in NS with 
unmethylated MGMT and wild type TP53 genes. No 
association has been found, however, between the 
SNP rs12435998 genotype and either the MGMT 
hypermethylation status or the TP53 mutation status 
(supplementary Table S1).
The association of VPA with DOX and PTX resulted 
in an increased anti-tumor effect, even if it was not verified 
in all cell lines.
The occurrence of the SNP rs1435998 influenced, 
in NS, the response to VPA alone whereas it did not affect 
the response to TMZ, DOX and PTX as either single or 
combined treatment. In AC, the SNP rs1435998 appeared 
to enhance the response to TMZ and DOX, alone or in 
combination with VPA, although this observation is 
limited to one cell line representative of each genotype 
(Figure 5B, 5C).
DISCUSSION
Our investigation started from the assumption that 
SEL1L is a putative tumor suppressor gene involved in the 
ERAD pathway and in the neoplastic progression [11, 12]. 
SEL1L has recently been reported to be significantly 
down-modulated in human PDA by aberrant 
microRNA up-regulation [13–15]. In gliomas, SEL1L is 
down-regulated as well, even though its mechanism is still 
unclear. It must be recalled that SEL1L SNP rs12435998 
was previously demonstrated to be an independent 
susceptibility factor in Alzheimer’s disease [23].
In this study we genotyped five genetic variants 
within SEL1L selected for their potential regulatory and 
coding functions in a series of 412 human brain tumors 
and 39 GBM cell lines.
We detected the two SNPs rs12435998 and 
rs11499034 in both glial and non-glial tumor series. 
The SNP rs12435998 was detected in astrocytic and 
oligodendroglial gliomas, with a higher frequency in 
malignant than in benign tumors. Its allelic frequency, 
however, was not significantly different either in 
comparison to controls or comparing benign to malignant 
tumors.
In non-glial tumors, the SNP rs12435998 
was detected in all tumor types, but it prevailed in 
meningiomas and ependymomas, without a statistically 
Figure 5: Effect of the SEL1L SNP rs12435998 on the response to drug treatments in GBM cell lines. A. Inhibitory effect 
of 2 mM VPA alone on the proliferation of NS and AC treated for 96 h. Effect of combination of 2 mM VPA with 50 μM TMZ B. with 1 μM 
DOX C. and with 50 nM PTX D. after 96 h exposure. Significant enhanced anti-proliferative effect is indicated with*. Data are average 
values ± standard deviation (SD) of three independent experiments, each performed in triplicate. 
Abbreviations: SEL1L, suppressor of Lin-12-like; SNP, single nucleotide polymorphism; GBM, glioblastoma multiforme; VPA, valproic 
acid; TMZ, temozolomide; DOX, doxorubicin; NS, neurospheres; AC, adherent cells; SNP, single nucleotide polymorphism; NS, 
neurospheres; AC, adherent cells.
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significant difference when compared to controls. This 
finding is in line with the significant association between 
an intergenic region 600 kb 5′ to SEL1L and meningioma 
progression recently described with two independent SNP 
cohorts [29]. In our series, however, the occurrence of the 
SNP rs12435998 did not correlate with the tumor grade. 
As a matter of fact, SEL1L maps on the critical region 
14q31.3, which typically displays LOH in atypical and, 
more frequently, in anaplastic meningiomas [30]. Its 
prevalence in meningiomas might also be interpreted in 
relation to their possible origin from the neural crest, as 
suggested at variance with the mesodermal origin [31].
In GBM patients, the survival analysis revealed 
a significantly longer median survival time in TC/CC 
variant genotype carriers compared to wild type patients, 
regardless of the post-surgical treatment and more 
evidently, after TMZ-based RT-CHT, both in MGMT 
methylated and unmethylated cases. The influence of 
the SNP rs12435998 did not result in the subgroup 
of 34 patients that were treated with RT alone since 
diagnosed before the Stupp’s protocol approval. These 
observations thus legitimize the discussion of the SNP 
rs12435998 as a novel prognostic and predictive marker 
for GBM patients.
In the oligodendroglioma group, most patients 
are still alive and no statistically significant result was 
obtained from survival analysis. As it is known, the 
effect of therapies on gliomas depends on the balance 
between sensitivity and resistance. The former is 
linked to the DNA exposure during replication, so that 
malignant gliomas are more sensitive to DNA damages 
by RT or TMZ. This explains why therapies are efficient 
on malignant gliomas, even though they display several 
resistance mechanisms, and why, within patients affected 
by oligodendrogliomas, which are less resistant and, at 
the same time, less malignant, the number of censored 
cases is high. It would be interesting to explore the 
frequency of this SNP in tumors characterized by a 
more prolonged OS and better prognosis (such as breast, 
colorectal, lung, esophageal and prostatic cancers) in 
order to highlight an association more pronounced with 
the tumor outcomes.
In spite of the possible functional effect of the 
SNP rs12435998 deduced by the in silico prediction, the 
analysis of SEL1L alternative transcripts on GBM cell 
lines carrying either the TC or CC variant genotype did not 
reveal aberrant splicing. Notably, the putative ESE motif 
predicted by two distinct bioinformatic tools (ESEfinder 
and Human Splicing Finder) acts as binding site for 
the splicing factor SC35, a member of the spliceosome 
required for the formation of the earliest ATP-dependent 
splicing complex and known to enhance the splicing of the 
Protein Kinase C δVIII (PKCδVIII) isoform in neurons 
[32], to play a potential role in neurogenesis, chromatin 
remodelling and self-renewal capacity of embryonic stem 
cells [33].
The SNP rs1149934 was detected in anaplastic 
and malignant astrocytic tumors, as well as in pure 
oligodendrogliomas, without association with brain tumor 
risk. Interestingly, the pGBM cell line heterozygous 
for this SNP (CV 20 NS), only developed in NS 
condition, suggesting a potential functional effect of this 
nucleotide variant on cell-cell and cell-matrix adhesion 
likely via fibronectin. The two single nucleotide variants 
c.–366T > C and c.–354T >C in the promoter region are 
rare variants, identified one for each tumor series. The 
missense variation p.Ser658Pro in exon 19 was never 
found in both series.
In GBM cell lines considered as either glioma 
initiating stem cells (GISCs) or glioma-associated stem 
cells (GASCs) [34], the assessment of the expression 
levels of SEL1L mRNA revealed higher level of 
transcript in AC compared to NS, regardless of the SNP 
rs12435998 genotype. This is in agreement with the 
differentiation of the former and the dedifferentiation 
of the latter, as previously demonstrated in murine 
neural stem cell lineage commitment [22] and in tumor 
transformation [16–20]. This finding is also consistent 
with the higher SOX2 and NOTCH1 expression, both 
markers of stemness, observed in NS compared to AC. 
An exception is represented by CTO3 NS and CTO3 
AC, carriers of the homozygous CC variant genotype, 
both expressing marked levels of the two genes. In fact, 
they share the same molecular profile of the respective 
primary tumor. This was interpreted as due to the 
occurrence in AC of a spectrum of maturation shifted 
towards stemness. The higher expression of Gadd45β 
found in general in AC compared to NS, correlates with 
their reduced proliferative potential.
Moreover, NS displayed by Western blotting 
analysis a supplementary band of 260 kDa that was not 
novel in our experience (IB, personal observations). 
It may represent a SEL1L precursor possibly related 
to the stemness property of NS, since it is not expressed 
in AC.
Within GBM cell lines, the SNP rs12435998 
down-regulates SEL1L expression only in NS and, at the 
same time, it increases the sensitivity to VPA, confirming 
a previous observation [21]. In fact, compared to wild 
type NS, the cell viability after VPA was significantly 
lower in NS with the TC/CC variant genotype. It is 
well known that nucleosome dense genome regions 
play a crucial role in controlling the elongation rate 
of transcription machinery and in regulating access of 
the promoter to transcription factors [35, 36]. Based on 
the large extension of intron 3 (20491 nt), we speculate 
that the minor allele C alters the nucleosome genome 
landscape with subsequent destabilization of exon-
intron junctions contributing to remarkable variation of 
the state–state mRNA levels. Moreover, the potential 
change in nucleosome packing might create a more 
permissive or restrictive state for the binding of specific 
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SEL1L repressor or activator related to stenmness such 
as previously described SC35.
In GBM cell lines, combined therapies of VPA with 
TMZ, DOX and PTX are more effective than the drugs 
alone. VPA appear able to potentiate the cytotoxicity and 
to improve the efficacy of the other chemotherapeutics, 
especially of TMZ, and more in NS than in AC. In general, 
the effect of a combined therapy on GBM cell lines 
depends on the action mechanisms of the various drugs, in 
association with the genetic and epigenetic asset of each 
cell line. As for TMZ, this effect should be interpreted 
according to both the differential hypermethylation status 
of the MGMT promoter region and the TP53 mutation 
status of the cell lines [37].
Our findings are consistent with the demonstrations 
that VPA is effective on GBM cell lines through 
inhibition of histone deacetylases (HDACs) [38] and that 
combined VPA + TMZ treatment is effective on glioma 
cell lines, mainly on TMZ-resistant ones, where VPA 
down-regulates at protein level the expression of the 
MGMT [39, 40].
The combined treatment of VPA with conventional 
TMZ-based RT-CHT has been previously proved to 
prolong survival in GBM patients [40], in line with the 
less recent demonstration that combined therapy could 
also be useful in malignant pediatric brain tumors [41]. 
In GBM patients, the combination of VPA with RT 
and CHT may thus appear as a rationale therapeutic 
option [42].
The potential relationship between the SNP 
rs12435998 and the increased response to TMZ found in 
AC may be in line with its predictive effect on our series 
of GBM patients.
In conclusion, this is the first study reporting a 
significant association of the SEL1L SNP rs12435998 
constitutive genetic variant with an improved OS in GBM 
patients, especially after conventional treatment with 
TMZ-based RT-CHT.
In vitro, we also demonstrated that the SNP 
rs12435998 down-regulates SEL1L expression in NS 
cultures derived from pGBMs and that it sensitizes these 
cells to VPA treatment.
The main limitation of the research is the low 
number of GBM cell lines used to test the in vitro 
cytotoxicity. Further studies are needed to confirm the 
putative association of the SNP rs12345998 with the 
response to standard TMZ-based RT-CHT on independent 
series of GBM patients and the in vitro response to VPA 
and TMZ, alone or in combination, in a larger panel of 
GBM cell lines.
Future implications of our observations include the 
possibility to test the SNP rs12435998 in the diagnostic 
practice of malignant gliomas and to consider the 
combined use of VPA and TMZ in the post-surgical 
therapeutic strategies of GBM patients.
MATERIALS AND METHODS
Ethics statement
Primary human GBM specimens for molecular 
genetics and cultures were obtained and used in 
compliance with the local institutional review board 
and Committee on Human Research and with the 
ethical human subject principles of the World Medical 
Association Declaration of Helsinki Research. Written 
informed consent was obtained from all patients after 
appropriate ethics approval of the CTO Hospital/Città 
della Salute e della Scienza (n. 487/2012).
Brain tumor specimens
A total of 412 brain tumors (328 gliomas and 
84 non-glial tumors) were analyzed. Three hundred eighty-
one formalin-fixed paraffin-embedded (FFPE) gliomas 
were obtained from the archive material of the Department 
of Medical Sciences of University of Turin/Città della 
Salute e della Scienza (Turin, Italy). The eighty-four FFPE 
non-glial tumors were obtained from the archive material 
of the Neuro-Bio-Oncology Center/Policlinico di Monza 
Foundation (Vercelli, Italy) (Table 5). Patients underwent 
either partial or total resection. The histologic diagnosis 
was performed according to the WHO guidelines [1]. 
GBMs were classified as primary (pGBM) or secondary 
tumors (sGBM) according to a previous histologically 
verified low grade glioma. From 41 patients, a matched 
constitutional DNA from blood/saliva was available 
as well.
Supplementary thirty-one brain tumors (22 gliomas 
and 9 non-glial tumors) were made available to us by 
Dr. Marc Sanson from Pitie-Salpétrière Hospital (Unite 
INSERM U495, 2. Federation de Neurologie Mazarin, 
Paris, France) (Table 5). They were diagnosed as above 
mentioned and selected based on the evidence of loss 
of heterozygosity (LOH) on chromosome 14q31.3 [43], 
SEL1L location site. Patient demographics are summarized 
in Table 5.
Cell lines
A total of 30 cell lines derived from surgically 
resected pGBMs were studied. Culture conditions have 
previously been described [25, 44].
Fourteen cell lines (CV1 NS, CV7 NS, 
CV10 NS, CV13 NS, CV17 NS, CV20 NS, CV21 
NS, NO3 NS, NO4 NS, NO6 NS, CTO3 NS, CTO5 
NS, CTO12 NS and CTO15 NS) were isolated in 
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 
supplemented with 20 ng/mL epidermal growth factor 
(EGF) and 10 ng/mL basic fibroblast growth factor (bFGF) 
for neurosphere (NS) assay (NSA). Sixteen cell lines 
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(CV2 AC, CV3 AC, CV4 AC, CV6 AC, CV8 AC, CV9 
AC, CV10 AC, CV17 AC, CV21 AC, NO2 AC, NO3 AC, 
NO4 AC, CTO3 AC, CTO5 AC, CTO12 AC and CTO15 
AC) developed in DMEM with 10% fetal bovine serum 
(FBS) for conventional monolayer growth and named 
adherent cell (AC). Both cultures were maintained in a 
5% O2 and 5% CO2 humidified atmosphere.
Cell line authentication from the respective primary 
tumor was obtained by Short Tandem Repeat (STR) 
profiling.
Two malignant glioma cell lines (U87-MG and 
010627) were kindly supplied by Dr. Rossella Galli 
(DIBIT San Raffaele, Milan, Italy) and maintained as both 
NS and AC.
Furthermore, five GBM cell lines (GliNS2, GBM2, 
G144, G166, G179) and two neuralized pluripotent 
human control stem cell lines (CB660 [fetal] and H9 
[embryonic]), kindly supplied by ISENET Stem Cell 
Biobank (www.isenet.it), were cultured in coated matrix 
according to Pollard’s, Sun’s and Cattaneo’s conditions, 
respectively [21, 45, 46].
All experiments on GBM cell lines were carried out 
with cells from passages 10–20. All cultures were checked 
for Mycoplasma contamination before experimental use 
(e-MycoTM Mycoplasma PCR Detection kit, iNtRON 
Biotechnology, Korea).
Glioma patient stratification
Survival data were available for 137 GBM 
patients. Out of these, 89 patients received post-
operative conventional fractionated RT (60 Gy 
total dose; 2 Gy × 5 days/week for 6 weeks). 
Fifty-five of these received concomitant CHT with TMZ 
(75 mg/m2/daily for 6 weeks) followed by adjuvant 
TMZ (200 mg/m2 × 5 days/week every 4 weeks for 
6–12 cycles) according to the EORT/NCIC-regime 
published by Stupp et al [2]. Thirty-four patients 
received RT and four CHT as single treatment with 
the above mentioned schedule. Fourteen patients had 
no post-surgical treatment whereas 30 cases were lost at 
follow-up.
Survival data were available for 58 
oligodendroglioma patients (33 WHO grade II and 
25 WHO grade III tumors). Out of these, sixteen 
received postoperative conventional fractionated RT 
Table 5: Patient demographics
Tumor type WHO grading Patients (N ) Gender (M/F) Mean age (years) and range
Glial tumors (N = 328)     
Pilocytic astrocytoma I 15 8/7 33 (9–68)
Diffuse and gemistocytic 
astrocytoma II 13 6/7 42 (23–68)
Anaplastic astrocytoma III 7 7/0 49 (24–75)
Primary GBM IV 180 112/68 60 (23–83)
Secondary GBM IV 6 4/2 47 (42–52)
Oligoastrocytoma II 9 7/2 41 (31–53)
Anaplastic 
oligoastrocytoma III 8 4/4 52 (37–71)
Oligodendroglioma II 49 28/21 47 (26–79)
Anaplastic 
oligodendroglioma III 41 22/16 55 (31–80)
Non-glial tumors (N = 84)     
Meningioma I 38 19/19 63 (48–78)
Meningioma II 8 5/3 58 (36–79)
Meningioma III 5 2/3 64 (54–80)
Schwannoma I 15 9/6 59 (25–82)
Ependymoma III 10 8/2 63 (48–84)
Medulloblastoma IV 8 6/2 26 (8–39)
Abbreviations: WHO, World Health Organization.
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(60 Gy total dose; 2 Gy × 5 days/week for 6 weeks). 
Fourteen of them also received either concomitant CHT 
with TMZ (75 mg/m2/daily for 6 weeks) or adjuvant 
TMZ (200 mg/m2 × 5 days/week every 4 weeks 
for 6–12 cycles) or both. Eight patients received 
TMZ (200 mg/m2 × 5 days/week every 4 weeks 
for 6–12 cycles) only, whereas five patients had no post-
surgical treatment. Twenty-nine patients were lost at 
follow-up.
DNA extraction
Genomic DNA (gDNA) from FFPE tumor samples 
and cell lines was isolated using the QIAamp DNA Mini 
kit (Qiagen NV, Venlo, The Netherlands). Constitutional 
gDNA from peripheral blood was extracted by a salting-
out protocol whereas from saliva with the Oragene 
DNA Collection kit (DNA Genotek Inc., Ontario, 
Canada, USA).
As reference control group, a series of 153 (59 men 
and 94 women, mean age 66.8 ± 11.93 years) unrelated, 
healthy and ethnicity-matched individuals was collected 
from medical students, university/hospital staff and blood 
donors [23, 24]. gDNA from this series was extracted 
using a silica-based method [48].
Single nucleotide genetic variant selection
The SEL1L gene spans more than 62.24 kb pairs 
within a “gene desert region” and displays only weak 
linkage disequilibrium pattern according to the HapMap 
CEU population data. A total of five single nucleotide 
genetic variants in the SEL1L gene (GenBank Reference 
sequence NM_005065) were selected (Table 6). Two of 
them (c.–366T > C and c.–354T > C) were first identified 
in the minimal promoter region of the SEL1L gene in 
lung carcinoma patients [47]. The c.341–88T > C genetic 
variant is a common SNP (rs12435998) within intron 3, 
containing potential binding sites for transcription factors 
involved in ER-induced stress, and it is a predicted 
splice site [23]. The c.485A > G (p.Asp162Gly) variant 
corresponds to the SNP rs11499034, maps in exon 4 
encoding for the fibronectin type II domain (FN2), and 
affects a highly conserved amino acid residue [24]. 
The amino acid change from Asp to Gly may have a 
disruptive role in the collagen binding. The c.1972T > C 
(p.Ser658Pro) variant in exon 19 has been described as 
somatic mutation responsible for the progressive early-
onset cerebellar ataxia in canine species [49]. Of note, 
the SEL1L gene is highly conserved between dog and 
human, with 98% identity at protein level (HomoloGene). 
The Ser658 residue located in the eleventh SEL1L-like 
repeat is completely conserved in all aligned vertebrates 
and maps within a functionally relevant domain for tumor 
growth inhibition [50].
Genotyping
Single nucleotide variant genotyping was performed 
by a SNaPShotTM SNP Multiplex Genotyping assay 
(Thermo Fisher Scientific Inc., Waltham, MA, USA) 
according to the manufacturer’s instructions. Genetic 
regions flanking each genetic variant were co-amplified 
using two multiplex polymerase chain reaction (PCR) 
primer pools (Table 6). PCR amplification was performed 
in a total volume of 12.5 μl containing 50 mM KCl, 
10 mM Tris–HCl (pH 8.3), 1.5 mM MgCl2, 250 μM 
of each dNTP, 0.365 U of AB Taq polymerase (AB 
Analitica, Padova, Italy), 10 pmol of each primer and 
50 ng of gDNA. A standard touchdown PCR protocol was 
used. The primer sequences for the SNaPShotTM reaction 
are available on demand. Capillary electrophoresis 
was performed on an ABI® 3130 Genetic Analyzer 
(Thermo Fisher Scientific Inc.) and data were collected 
Table 6: SEL1L nucleotide genetic variants analyzed in the current study
Nucleotide 
change
Amino acid 
change
Location SNP ID Reference PCR primers from 5′ to 3′ (forward/
reverse)
c.–366T > C - Promoter - [47] CTTGTGAATCCATAGCCTTGA/ATTGTACGAAGCTCCCACAC
c.–354T > C - Promoter - [47] CTTGTGAATCCATAGCCTTGA/ATTGTACGAAGCTCCCACAC
c.341–88T > C - Intron 3 rs12435998 [23] TGCTAGCCCTTTTATGTTCC/TGCCCTAGACATAAAGCAATG
c.485A > G p.Asp162Gly Exon 4 rs11499034 [24] TGCTAGCCCTTTTATGTTCC/TGCCCTAGACATAAAGCAATG
c.1972T > C p.Ser658Pro Exon 19 - [48] AGCATGTCAATGGGAGGAG/ TGCAAGTATTTTCCCCAATC
Abbreviations: SEL1L, suppressor of Lin-12-like; WHO, World Health Organization; SNP, single nucleotide polymorphism; 
PCR, polymerase chain reaction.
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using GeneMapper v4.0 software (Thermo Fisher 
Scientific Inc.).
In silico analysis
The putative functional relevance of the two 
analyzed missense variations was evaluated with 
PolyPhen-2 (http://genetics.bwh. harvard.edu/pph2/), 
SNAP (https://rostlab.org/services/snap/) and pMUT 
(http://mmb.pcb.ub.es/PMut/) software.
The putative effect of the other nucleotide variations 
on splice sites was evaluated using the ESEfinder scoring 
matrix (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder 
.cgi?process=home) and Human Splicing Finder (http://
www.umd.be/HSF/).
RNA isolation and quantitative real time  
(qRT)-PCR in GBM cell lines
Total RNA was purified from 18 GBM cell lines 
with the RNeasy Mini kit (Qiagen). One microgram of 
RNA was reverse-transcribed using random primers 
with the High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific Inc.), according to the 
manufacturer’s instructions.
qRT-PCR for SEL1L, SOX2, NOTCH1 and Gadd45β 
genes was performed as already described [21]. Reactions 
were carried out using the Thermo Scientific Maxima 
SYBR Green/ROX qPCR Master Mix (Thermo Fisher 
Scientific Inc.) on a Rotor-Gene Q MDx instrument 
(Qiagen). The qRT-PCR conditions were the following: 
an initial denaturation step at 95°C for 10 min followed 
by 40 cycles at 95°C for 15 sec, 60°C for 30 sec, 72°C 
for 30 sec and final melting. Relative fold changes in 
the expression of genes of interest compared to the 
housekeeping gene GADPH were determined by the 
comparative ΔΔCt method. All assays were performed in 
triplicate.
SEL1L putative alternative transcripts were 
investigated in the same panel of 18 GBM cell 
lines by RT-PCR using specific primers: SEL1L-F: 
5′-gaaggcagccaggatgaatcc-3′ and SEL1L-R: 
5′-gcccccaagagctccaaatg-3′. The PCR conditions consisted 
of an initial denaturation step at 95°C for 3 min, followed 
by 32 cycles at 94°C for 1 min, 60°C for 1 min, 72°C for 
1 min, with a final extension at 72°C for 5 min. All PCR 
products were electrophoresed on a 1.2% agarose gel and 
stained with ethidium bromide.
Protein extraction and Western blotting  
analysis
Whole protein extracts from 11 cell lines (NO3 NS, 
NO4 NS, CTO3 NS, CV4 AC, CV6 AC, CV9 AC, CV10 
AC, CV17 AC, NO3 AC, NO4 AC and CTO3 AC) were 
isolated in a lysis buffer containing 50 mM Tris HCl pH 
7.6, 150 mM NaCl, 1% Nonidet P-40 and supplemented 
with protease inhibitors (Pierce Biotechnology, Rockford, 
IL, USA). After protein quantification by Bradford assay 
(Thermo Scientific Inc.), equal amounts of protein extracts 
were resolved by a 10% SDS-PAGE and transferred 
onto a PVDF membrane. Blots were probed with a 
mouse monoclonal [16] and a goat polyclonal (Santa 
Cruz Biotechnology Inc., Dallas, TX, USA) anti-SEL1L 
antibody and then treated with the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibody (GE 
Healthcare Life Science, MA, USA). Proteins were 
detected by enhanced chemiluminescence (Genespin, 
Milan, Italy). An anti-β-tubulin antibody (Sigma Aldrich 
Co., St. Louis, MO, USA) was used to normalize sample 
loading and transfer. Hybridizations were performed in a 
X-BlotP100 hybridization chamber (www.isenet.it).
Drug treatments and cytotoxicity assay
VPA (from Sigma Aldrich Co.) was dissolved 
in sterile water, whereas TMZ, doxorubicin (DOX) 
and paclitaxel (PTX) (all from Sigma) were dissolved 
in 100% dimethylsulfoxide (DMSO) for stock 
solutions. Dilutions for all drug treatments were 
made extemporaneously in culture medium, so that 
the final concentration of DMSO never exceeded 
0.3% (v/v).
The inhibitory effect of VPA was evaluated on six 
NS (NO3 NS, NO4 NS, CTO3 NS, CTO5 NS, CTO12 
NS, CTO15 NS) and on three AC (NO3 AC, CTO3 AC 
and CTO15 AC). On the same cell lines we investigated 
the action of TMZ, DOX and PTX alone. The in vitro 
cytotoxicity of the four drugs, alone or combined, 
was evaluated assessing after exposure the number 
of viable cells by the 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyl-tetrazolium bromide (MTT) assay kit 
(Roche Diagnostics Corporation, Indianapolis, IL, USA) 
measuring formazan release at 570 nm by a microplate 
reader (Synergy HT, BioTek Instruments Inc., Winooski, 
VT, USA). For NS, cell counts were confirmed by 
Trypan Blue assay using a TC20 automated cell 
counter (Bio-Rad Laboratories, Hercules, CA, USA). 
Cytotoxicity was expressed as number of viable cells 
as percentage of control untreated cells. For each drug 
the IC50 value, that is the concentration required for 
50% cell growth inhibition compared with untreated 
controls, was calculated by non-linear regression at 
96 hours (h); based on these data, a concentration 
of 2 mM for VPA, 50 μM for TMZ, 1 μM for DOX 
and 50 nM for PTX were chosen for the following 
combination experiments.
To evaluate the effect of the association of VPA 
with the other three chemotherapeutics, cells were treated 
combining VPA with TMZ, DOX or PTX at the doses 
above mentioned and, after 96 h incubation, the cell 
viability was assessed as before described.
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Statistical methods
Association analysis was evaluated using 2 × 2 
contingency tables by the Chi-square (χ2) or the two-tailed 
Fisher’s exact test, as appropriate. The Student’s t-test was 
used to compare the SNP rs12435998 genotype with the 
age at diagnosis.
OS was defined as the time between the histological 
diagnosis and patient’s death or last follow-up. Patient 
alive at last follow-up were considered censored events. 
Survival curves were estimated using the Kaplan-Meier 
method and differences between them were compared by 
the Log-rank test (Mantel-Cox). Analysis was carried out 
by SPSS v21.0 software (SPSS Inc., Chicago, IL, USA).
For the cytotoxicity assays, the level of significance 
was determined by the Student’s t test. P values < 0.05 
were considered as statistically significant.
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